BeStock  
Stocks › Biotechnology › GMAB

Genmab GMAB

US equityMarket cap rank #628Biotechnology
$50.60 −$0.75 (-1.46%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $50.02 -1.15%
Open$51.57
Prev close$51.35
Day range$50.24 – $51.72
Volume2.90M
Market cap$31.20B
P/E (TTM)43.2
Dividend yield–

Earnings

Average move on report day±2.9%last 16 reports
Closed higher7 of 1644% of the time
Best reaction+5.5%
Worst reaction-5.7%

Stock move on the day after each report

+4.4%2023/Q4-3.6%2024/Q1+2.3%2024/Q2-1.8%2024/Q3+4.2%2024/Q4-5.7%2025/Q1+5.5%2025/Q2-1.2%2025/Q3-0.1%2025/Q4-3.0%2026/Q1+1.9%2026/Q2-4.3%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q35 Nov 2026None±6.2%-4.32%Within range
2026/Q26 Aug 2026None±12.1%+1.95%Within range
2026/Q17 May 2026None±11.1%-2.98%Within range
2025/Q417 Feb 2026None±4.5%-0.10%Within range
2025/Q36 Nov 2025None±10.5%-1.20%Within range
2025/Q27 Aug 2025None±10.3%+5.49%Within range
2025/Q18 May 2025None±14.1%-5.73%Within range
2024/Q412 Feb 2025None±14.7%+4.24%Within range
2024/Q36 Nov 2024None±11.6%-1.85%Within range
2024/Q28 Aug 2024None±14.0%+2.31%Within range
2024/Q12 May 2024None±8.7%-3.58%Within range
2023/Q414 Feb 2024None±11.2%+4.39%Within range
2023/Q37 Nov 2023None±11.0%+2.32%Within range
2023/Q23 Aug 2023None±13.3%-0.76%Within range
2023/Q110 May 2023None±10.4%+1.95%Within range
2022/Q422 Feb 2023None±13.5%-3.26%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • DARZALEX$751.00M 63.3%
  • Kesimpta$149.00M 12.6%
  • Net product sales$149.00M 12.6%
  • Other$55.00M 4.6%
  • TEPEZZA$36.00M 3.0%
  • Collaboration revenue$17.00M 1.4%
  • Reimbursement revenue$15.00M 1.3%
  • License revenue$10.00M 0.8%
  • Milestone revenue$5.00M 0.4%

Latest reported quarter: Q3, ended Sep 2026

Revenue$1.19B+16.1% YoY
Operating profit$441.00M-3.9% YoY
Net profit$342.00M-14.7% YoY
Diluted EPS$0.55-14.7% YoY
Free cash flow$509.00M-4.7% YoY
Operating cash flow$520.00M

Revenue, last 8 quarters

$923.0MDec '24$715.0MMar '25$925.0MJun '25$1.0BSep '25$1.1BDec '25$896.0MMar '26$1.2BJun '26$1.2BSep '26

Net profit, last 8 quarters

$552.0MDec '24$195.0MMar '25$336.0MJun '25$401.0MSep '25$31.0MDec '25$53.0MMar '26$303.0MJun '26$342.0MSep '26

Profitability & balance sheet

Gross margin92.7%
Operating margin30.6%
Net margin17.0%
Return on equity12.1%
Return on assets7.3%
Return on invested capital11.1%
Current ratio2.45
Liabilities / assets51.0%
Cash & investments$1.86B
Total debt$5.17B
Net cash (debt)-$3.31B
Free cash flow / sales19.6%

Discussion

No comments yet — be the first to weigh in on GMAB.

Sign in to join the discussion.

Scroll to Top